

## LISTING OF CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Previously presented) A method of improving tolerance to a xenograft comprising: immunising a mammal with an immunogen comprising at least one T-cell epitope and at least one porcine polypeptide B-cell epitope, wherein said B-cell epitope is capable of mediating rejection of said xenograft.

2. (Currently amended) A method according to Claim 1, wherein said B-cell epitope is a peptide ~~derived from~~ comprising at least 9 contiguous amino acids of a porcine CD86 polypeptide.

3-4. (Cancelled).

5. (Currently amended) A method according to Claim 2, wherein said peptide is ~~selected from at least one peptide represented in Figure 26~~ comprises residues 113-121 of SEQ ID NO: 14, or residues 151-162 of SEQ ID NO: 14.

6. (Previously presented) A method according to Claim 1, wherein said T-cell epitope comprises a tetanus toxoid polypeptide.

7. (Previously presented) A composition comprising an immunogen characterised in that said immunogen comprises at least one B-cell epitope and at least one T-cell epitope wherein said B-cell epitope comprises a porcine epitope involved in mediating xenograft rejection.

8. (Previously presented) A composition according to Claim 7, wherein said porcine epitope comprises a porcine polypeptide expressed by vascular endothelial cells of said xenograft.

9. (Currently amended) A composition according to Claim 7, wherein said B-cell epitope is ~~derived from~~ at least 9 contiguous amino acids of a porcine CD86.

10-11. (Cancelled)

12. (Currently amended) A composition according to Claim 9, wherein said B-cell epitope comprises ~~at least one peptide as represented in Figure 26~~ residues 113-121 of SEQ ID NO: 14, or residues 151-162 of SEQ ID NO: 14.

13. (Previously presented) A composition according to Claim 9, wherein said B-cell epitope comprises an extracellular domain of CD86.

14. (Previously presented) A composition according to Claim 7, wherein said T-cell epitope comprises a tetanus toxoid epitope.

15. (Previously presented) A composition according to Claim 7, wherein said composition further comprises a carrier capable of enhancing the immune response to said immunogen.

16-23. (Cancelled).

24. (Previously presented) The method Claim 1, wherein said B-cell epitope has less than 75% sequence identity to a corresponding region of an equivalent human polypeptide.

25. (Previously presented) The composition of Claim 7, wherein said B-cell epitope has less than 75% sequence identity to a corresponding region of an equivalent human polypeptide.

26. (Cancelled).

27. (Currently amended) The method according to ~~Claim 5~~Claim 2, wherein said peptide comprises at least nine contiguous amino acids from SEQ ID NO: 14.

28. (Currently amended) The composition according to ~~Claim 12~~Claim 7, wherein said peptide comprises at least nine contiguous amino acids from SEQ ID NO: 14.